Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics and irinotecan therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 15 Nov 2006

Hahn Kristine K, Wolff James J, Kolesar Jill M

Abstract excerpt

PURPOSE: Irinotecan metabolism, irinotecan pharmacogenetic research, and the role of genetic testing before administration of the drug are reviewed. SUMMARY: Irinotecan is approved worldwide for the treatment of metastatic colorectal cancer but causes dose-limiting neutropenia and diarrhea. When severe, these can lead to dehydration, infection, patient discomfort, additional medication requirements,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neutropenia
Share to Practice Guidelines as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Bilirubin

Share to Camptothecin

Share to Clinical Trials as Topic

Share to Diarrhea

Source

Identifiers

PMID: 17090741
DOI: 10.2146/ajhp060155

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics and irinotecan therapy.PMID 17090741Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

Insights, challenges, and future directions in irinogenetics.Semantic proximity Read ↗

Clinical Pharmacogenetics of Irinotecan (CPT-11)Semantic proximity Read ↗

An overview of the recent progress in irinotecan pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetics of irinotecan toxicitySemantic proximity Read ↗

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.Semantic proximity Read ↗

[UGT1A1 Genotyping for Proper Use of Irinotecan].Semantic proximity Read ↗

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.Semantic proximity Read ↗

Pharmacogenetic approach for cancer treatment-tailored medicine in practice.Semantic proximity Read ↗

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.